By blocking inhibitory pathways like PD-1 and CTLA-4, these therapies can lead to the loss of immune tolerance, causing the immune system to attack healthy tissues and resulting in conditions such as colitis, pneumonitis, and hepatitis. The gene discussed is CTLA4; the disease is hepatitis A virus infection.